{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T17:38:34Z","timestamp":1792172314910,"version":"4.4.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"published-print":{"date-parts":[[2012,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>The aim of this study is to analyse <jats:italic>CDKN2A<\/jats:italic> methylation using pyrosequencing on a large cohort of colorectal cancers and corresponding non-neoplastic tissues. In a second step, the effect of methylation on clinical outcome is addressed.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Primary colorectal cancers and matched non-neoplastic tissues from 432 patients underwent <jats:italic>CDKN2A<\/jats:italic> methylation analysis by pyrosequencing (PyroMarkQ96). Methylation was then related to clinical outcome, microsatellite instability (MSI), and <jats:italic>BRAF<\/jats:italic> and <jats:italic>KRAS<\/jats:italic> mutation. Different amplification conditions (35 to 50 PCR cycles) using a range of 0-100% methylated DNA were tested.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Background methylation was at most 10% with \u226535 PCR cycles. Correlation of observed and expected values was high, even at low methylation levels (0.02%, 0.6%, 2%). Accuracy of detection was optimal with 45 PCR cycles. Methylation in normal mucosa ranged from 0 to &gt;90% in some cases. Based on the maximum value of 10% background, positivity was defined as a \u226520% difference in methylation between tumor and normal tissue, which occurred in 87 cases. <jats:italic>CDKN2A<\/jats:italic> methylation positivity was associated with MSI (p = 0.025), <jats:italic>BRAF<\/jats:italic> mutation (p &lt; 0.0001), higher tumor grade (p &lt; 0.0001), mucinous histology (p = 0.0209) but not with <jats:italic>KRAS<\/jats:italic> mutation. <jats:italic>CDKN2A<\/jats:italic> methylation had an independent adverse effect (p = 0.0058) on prognosis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>The non-negligible <jats:italic>CDKN2A<\/jats:italic> methylation of normal colorectal mucosa may confound the assessment of tumor-specific hypermethylation, suggesting that corresponding non-neoplastic tissue should be used as a control. <jats:italic>CDKN2A<\/jats:italic> methylation is robustly detected by pyrosequencing, even at low levels, suggesting that this unfavorable prognostic biomarker warrants investigation in prospective studies.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1479-5876-10-173","type":"journal-article","created":{"date-parts":[[2012,8,27]],"date-time":"2012-08-27T12:14:34Z","timestamp":1346069674000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":54,"title":["Characterization of CDKN2A(p16) methylation and impact in colorectal cancer: systematic analysis using pyrosequencing"],"prefix":"10.1186","volume":"10","author":[{"given":"Michel P","family":"Bihl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"Foerster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Lugli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inti","family":"Zlobec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,8,27]]},"reference":[{"key":"1202_CR1","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1002\/emmm.201000099","volume":"2","author":"LA Carragher","year":"2010","unstructured":"Carragher LA, Snell KR, Giblett SM, Aldridge VS, Patel B, Cook SJ, Winton DJ, Marais R, Pritchard CA: V600EBraf induces gastrointestinal crypt senescence and promotes tumour progression through enhanced CpG methylation of p16INK4a. EMBO Mol Med. 2010, 2: 458-471. 10.1002\/emmm.201000099.","journal-title":"EMBO Mol Med"},{"key":"1202_CR2","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1038\/modpathol.2011.43","volume":"24","author":"L Kriegl","year":"2011","unstructured":"Kriegl L, Neumann J, Vieth M, Greten FR, Reu S, Jung A, Kirchner T: Up and downregulation of p16(Ink4a) expression in BRAF-mutated polyps\/adenomas indicates a senescence barrier in the serrated route to colon cancer. Mod Pathol. 2011, 24: 1015-1022. 10.1038\/modpathol.2011.43.","journal-title":"Mod Pathol"},{"key":"1202_CR3","doi-asserted-by":"publisher","first-page":"2088","DOI":"10.1053\/j.gastro.2009.12.066","volume":"138","author":"B Leggett","year":"2010","unstructured":"Leggett B, Whitehall V: Role of the serrated pathway in colorectal cancer pathogenesis. Gastroenterology. 2010, 138: 2088-2100. 10.1053\/j.gastro.2009.12.066.","journal-title":"Gastroenterology"},{"key":"1202_CR4","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1002\/ijc.25432","volume":"128","author":"K Shima","year":"2011","unstructured":"Shima K, Nosho K, Baba Y, Cantor M, Meyerhardt JA, Giovannucci EL, Fuchs CS, Ogino S: Prognostic significance of CDKN2A (p16) promoter methylation and loss of expression in 902 colorectal cancers: Cohort study and literature review. Int J Cancer. 2011, 128: 1080-1094. 10.1002\/ijc.25432.","journal-title":"Int J Cancer"},{"key":"1202_CR5","doi-asserted-by":"publisher","first-page":"8681","DOI":"10.1073\/pnas.96.15.8681","volume":"96","author":"M Toyota","year":"1999","unstructured":"Toyota M, Ahuja N, Ohe-Toyota M, Herman JG, Baylin SB, Issa JP: CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci U S A. 1999, 96: 8681-8686. 10.1073\/pnas.96.15.8681.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1202_CR6","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1038\/nprot.2007.314","volume":"2","author":"J Tost","year":"2007","unstructured":"Tost J, Gut IG: DNA methylation analysis by pyrosequencing. Nat Protoc. 2007, 2: 2265-2275. 10.1038\/nprot.2007.314.","journal-title":"Nat Protoc"},{"key":"1202_CR7","doi-asserted-by":"publisher","first-page":"9821","DOI":"10.1073\/pnas.93.18.9821","volume":"93","author":"JG Herman","year":"1996","unstructured":"Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB: Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A. 1996, 93: 9821-9826. 10.1073\/pnas.93.18.9821.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1202_CR8","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1158\/1940-6207.CAPR-10-0047","volume":"3","author":"K Wallace","year":"2010","unstructured":"Wallace K, Grau MV, Levine AJ, Shen L, Hamdan R, Chen X, Gui J, Haile RW, Barry EL, Ahnen D: Association between folate levels and CpG Island hypermethylation in normal colorectal mucosa. Cancer Prev Res (Phila). 2010, 3: 1552-1564. 10.1158\/1940-6207.CAPR-10-0047.","journal-title":"Cancer Prev Res (Phila)"},{"key":"1202_CR9","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1155\/2011\/157829","volume":"30","author":"N Vasiljevic","year":"2011","unstructured":"Vasiljevic N, Wu K, Brentnall AR, Kim DC, Thorat MA, Kudahetti SC, Mao X, Xue L, Yu Y, Shaw GL: Absolute quantitation of DNA methylation of 28 candidate genes in prostate cancer using pyrosequencing. Dis Markers. 2011, 30: 151-161.","journal-title":"Dis Markers"},{"issue":"3","key":"1202_CR10","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1038\/ajg.2011.457","volume":"107","author":"T Kimura","year":"2012","unstructured":"Kimura T, Yamamoto E, Yamano HO, Suzuki H, Kamimae S, Nojima M, Sawada T, Ashida M, Yoshikawa K, Takagi R: A Novel Pit Pattern Identifies the Precursor of Colorectal Cancer Derived From Sessile Serrated Adenoma. Am J Gastroenterol. 2012, 107 (3): 460-469. 10.1038\/ajg.2011.457.","journal-title":"Am J Gastroenterol"},{"key":"1202_CR11","doi-asserted-by":"publisher","first-page":"e27889","DOI":"10.1371\/journal.pone.0027889","volume":"6","author":"K Konishi","year":"2011","unstructured":"Konishi K, Watanabe Y, Shen L, Guo Y, Castoro RJ, Kondo K, Chung W, Ahmed S, Jelinek J, Boumber YA: DNA methylation profiles of primary colorectal carcinoma and matched liver metastasis. PLoS One. 2011, 6: e27889-10.1371\/journal.pone.0027889.","journal-title":"PLoS One"},{"key":"1202_CR12","doi-asserted-by":"publisher","first-page":"4531","DOI":"10.1158\/1078-0432.CCR-10-0763","volume":"17","author":"M Tanaka","year":"2011","unstructured":"Tanaka M, Chang P, Li Y, Li D, Overman M, Maru DM, Sethi S, Phillips J, Bland GL, Abbruzzese JL, Eng C: Association of CHFR promoter methylation with disease recurrence in locally advanced colon cancer. Clin Cancer Res. 2011, 17: 4531-4540. 10.1158\/1078-0432.CCR-10-0763.","journal-title":"Clin Cancer Res"},{"key":"1202_CR13","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1002\/cncr.25737","volume":"117","author":"JB Ahn","year":"2011","unstructured":"Ahn JB, Chung WB, Maeda O, Shin SJ, Kim HS, Chung HC, Kim NK, Issa JP: DNA methylation predicts recurrence from resected stage III proximal colon cancer. Cancer. 2011, 117: 1847-1854. 10.1002\/cncr.25737.","journal-title":"Cancer"},{"key":"1202_CR14","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.leukres.2010.10.001","volume":"35","author":"N Zainuddin","year":"2011","unstructured":"Zainuddin N, Kanduri M, Berglund M, Lindell M, Amini RM, Roos G, Sundstrom C, Enblad G, Rosenquist R: Quantitative evaluation of p16(INK4a) promoter methylation using pyrosequencing in de novo diffuse large B-cell lymphoma. Leuk Res. 2011, 35: 438-443. 10.1016\/j.leukres.2010.10.001.","journal-title":"Leuk Res"},{"key":"1202_CR15","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1053\/j.gastro.2010.12.035","volume":"140","author":"R Jover","year":"2011","unstructured":"Jover R, Nguyen TP, Perez-Carbonell L, Zapater P, Paya A, Alenda C, Rojas E, Cubiella J, Balaguer F, Morillas JD: 5-Fluorouracil adjuvant chemotherapy does not increase survival in patients with CpG island methylator phenotype colorectal cancer. Gastroenterology. 2011, 140: 1174-1181. 10.1053\/j.gastro.2010.12.035.","journal-title":"Gastroenterology"},{"key":"1202_CR16","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1245\/s10434-009-0901-y","volume":"17","author":"JC Kim","year":"2010","unstructured":"Kim JC, Choi JS, Roh SA, Cho DH, Kim TW, Kim YS: Promoter methylation of specific genes is associated with the phenotype and progression of colorectal adenocarcinomas. Ann Surg Oncol. 2010, 17: 1767-1776. 10.1245\/s10434-009-0901-y.","journal-title":"Ann Surg Oncol"},{"key":"1202_CR17","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1159\/000012023","volume":"57","author":"JT Liang","year":"1999","unstructured":"Liang JT, Chang KJ, Chen JC, Lee CC, Cheng YM, Hsu HC, Wu MS, Wang SM, Lin JT, Cheng AL: Hypermethylation of the p16 gene in sporadic T3N0M0 stage colorectal cancers: association with DNA replication error and shorter survival. Oncology. 1999, 57: 149-156. 10.1159\/000012023.","journal-title":"Oncology"},{"key":"1202_CR18","first-page":"935","volume":"10","author":"K Maeda","year":"2003","unstructured":"Maeda K, Kawakami K, Ishida Y, Ishiguro K, Omura K, Watanabe G: Hypermethylation of the CDKN2A gene in colorectal cancer is associated with shorter survival. Oncol Rep. 2003, 10: 935-938.","journal-title":"Oncol Rep"},{"key":"1202_CR19","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/s00432-009-0688-z","volume":"136","author":"H Mitomi","year":"2010","unstructured":"Mitomi H, Fukui N, Tanaka N, Kanazawa H, Saito T, Matsuoka T, Yao T: Aberrant p16((INK4a)) methylation is a frequent event in colorectal cancers: prognostic value and relation to mRNA expression and immunoreactivity. J Cancer Res Clin Oncol. 2010, 136: 323-331. 10.1007\/s00432-009-0688-z.","journal-title":"J Cancer Res Clin Oncol"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1479-5876-10-173.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T20:12:04Z","timestamp":1630527124000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/1479-5876-10-173"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8,27]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["1202"],"URL":"https:\/\/doi.org\/10.1186\/1479-5876-10-173","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,8,27]]},"assertion":[{"value":"13 April 2012","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2012","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2012","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"173"}}